CNBC Pro: Morgan Stanley says this global biotech stock could soar 398% in the next year
Analysts at Morgan Stanley think one global biotech company's stock could soar 398% in the next year. The company's latest regenerative medicine has completed phase 2 trials in Japan and U.S. and is awaiting final approval.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む: